Ronald Harold Wilfred Cooper - 17 Sep 2021 Form 4 Insider Report for ALBIREO PHARMA, INC.

Role
President and CEO, Director
Signature
/s/ Jason Duncan, Attorney-in-fact
Issuer symbol
N/A
Transactions as of
17 Sep 2021
Net transactions value
-$11.73
Form type
4
Filing time
20 Sep 2021, 16:03:36 UTC
Next filing
20 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALBO Common Stock Options Exercise $229,762 +11,973 +21% $19.19 68,433 17 Sep 2021 Direct F1, F2
transaction ALBO Common Stock Tax liability $229,774 -7,760 -11% $29.61 60,673 17 Sep 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALBO Stock Option (right to buy) Options Exercise $0 -11,973 -22% $0.000000 43,027 17 Sep 2021 Common Stock 11,973 $19.19 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On September 17, 2021, the reporting person exercised options to purchase 11,973 shares of common stock and delivered 7,760 shares of common stock held by the reporting person to the issuer to pay the exercise price of the options. The delivery of the shares by the reporting person to pay the exercise price of the options was previously approved by the issuer's compensation committee in accordance with Rule 16b-3 and the issuer has retained the shares delivered to it by the reporting person.
F2 Represents 19,733 shares of common stock and 48,700 restricted stock units.
F3 Represents 11,973 shares of common stock and 48,700 restricted stock units.
F4 This option is fully vested.